Risk Management Plans Are In Fact A “Big Deal,” FDA Tells Gilead

FDA's citation of Gilead for downplaying the risk management plan for its pulmonary arterial hypertension product Letairis (ambrisentan) is noteworthy for what it doesn't cite as much for what it does

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet